You just read:

New Subanalyses of the RE-LY Trial Showed Pradaxa Reduced Stroke Risk in Patients With Varying CHA2DS2-VASc Scores and Types of Non-Valvular Atrial Fibrillation

News provided by

Boehringer Ingelheim Pharmaceuticals, Inc.

Apr 04, 2011, 09:15 ET